Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 for Newly Diagnosed AL Amyloidosis
NCT07151690Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gamgertamig in systemic light chain amyloidosis, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Sep 2025; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT07151690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07151690.